|Dr. Vasant Narasimhan||Chief Exec. Officer||5.09M||N/A||1976|
|Mr. Harry Kirsch||Chief Financial Officer||2.68M||N/A||1965|
|Mr. Steffen Lang Ph.D.||Global Head of Technical Operations||2.02M||N/A||1967|
|Dr. Klaus Moosmayer Ph.D.||Chief Ethics, Risk & Compliance Officer||1.33M||N/A||1968|
|Dr. John Tsai||Head of Global Drug Devel. & Chief Medical Officer||2.3M||N/A||1967|
|Mr. Robert Weltevreden||Head of Customer & Technology Solutions||1.57M||N/A||1969|
|Ms. Susanne Schaffert Ph.D.||Pres of Novartis Oncology||3.01M||N/A||1967|
|Mr. Richard Saynor||Chief Exec. Officer of Sandoz||3.8M||N/A||1967|
|Dr. James E. Bradner||Pres of Novartis Institutes for Biomedical Research||3.2M||N/A||1972|
|Ms. Marie-France Tschudin||Pres of Novartis Pharmaceuticals||2.1M||N/A||1971|
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG’s ISS governance QualityScore as of 26 September 2021 is 2. The pillar scores are Audit: 2; Board: 2; Shareholder rights: 9; Compensation: 1.